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Abstract 
 Pantothenic acid (vitamin B5) is a water-soluble B-complex vitamin. 
It is of biologic importance because of its incorporation into coenzyme A and 
acyl carrier protein. Coenzyme A is an indispensable cofactor in all living 
organisms, where it functions in over 70 enzymatic pathways. Most bacteria, 
plants, and fungi synthesizes pantothenic acid; thus, the vitamin is found 
virtually everywhere in nature. Therefore, a naturally occurring vitamin 
deficiency in humans does not occur. Several clinical trials have been 
undertaken in humans using pantothenic acid supplementation in various 
medical fields. Unfortunately, firm conclusions regarding therapeutic 
effectiveness cannot be drawn from many of these studies. However, it has 
been suggested that there is a beneficial effect of pantethine on 
hyperlipidemia. Cysteamine treatment, a metabolite of the degradation of 
coenzyme A, has dramatically changed the course of the cystinosis; and 
clinical trials of this compound are underway in other medical fields. In the 
last few decades, several studies have pointed out the great interest of the 
inhibition of the coenzyme A metabolic pathway as an attractive target in 
developing new antimicrobial agents. Furthermore, recent research on 
coenzyme A metabolic enzymes has led to the discovery of uniquely non-
metabolic roles for both enzymes and their metabolites, thus opening an 
exciting field of investigation.  In the present mini-review, we describe the 
current understanding of the pantothenic acid medical aspects and provide an 
overview on future potential therapeutic indications for this vitamin and its 
metabolic byproducts. 
 
Keywords: Pantothenic acid, pantothenate, vitamin B5, coenzyme A, 
cystinosis, new targets for antimicrobials  
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Introduction 
 Pantothenic acid (also known as pantothenate or vitamin B5) is a 
water-soluble B-complex vitamin (1, 23), that was discovered in 1931 by 
chemist Roger J. Williams (1893-1988) during his studies on the vitamin B 
complex (26). Williams observed that an acidic substance was capable of 
stimulating the growth of strains on yeast Saccharomyces cerevisiae (42). In 
1933, he named the substance pantothenic acid from the Greek word 
panthos, meaning “from all sides” (42). However, it was given this name 
because of its widespread presence in food (42). Pantothenic acid was 
isolated and extracted from liver by Williams and his colleagues in 1939, as 
an impure substance (about 40% pure). Thus, the initial isolation produced 
3g of pantothenic acid from 250kg of sheep liver (26). In 1939, a partial 
synthesis of pantothenic acid was carried out independently by Williams in 
Oregon and Conrad A. Elvehjem (1901-1962) in Wisconsin (43). Finally, the 
synthesis of pantothenic acid was achieved in 1940 by American biochemist, 
Karl Folkers (1906-1997) and colleagues at Merck and Company in Rawhay, 
N.J. (38). Therefore, the structure of the pantothenic acid was determined by 
a stepwise degradation and synthesis (26). 
 Pantothenic acid is pantoic acid linked with β-alanine through an 
amide bond (27). Pantothenic acid is of biologic importance because of its 
incorporation into coenzyme A (CoA) and acyl carrier protein (ACP), on 
which acetylation and acylation, respectively, and other interactions depend. 
CoA is an indispensable cofactor in all living organisms, where it functions 
in over 70 enzymatic pathways, including fatty acid oxidation, carbohydrate 
metabolism, pyravate degradation, amino acid catabolism, heme synthesis, 
acetylcholine synthesis, and phase II detoxification acetylation (1). On the 
other hand, ACP is an essential component of the fatty acid synthase 
complex required for fatty acid elongation (1). 
 Subsequently, only the Dextrorotatory (D) isomer of pantothenic acid 
–D-pantothenic acid- possesses biologic activity (23). The reactive 
component of both CoA and ACP is not the pantothenic acid molecule, but 
rather the sulfhydryl (SH) group donated from cysteine (1). Pantethine is the 
stable disulfate form of pantetheine. It is the metabolic substrate that 
constitutes the active part of CoA and ACP (1). Thus, the disulphide form of 
pantothenic acid –pantethine- is considered to be the most active form of 
vitamin B5 because it contains the sulfhydryl-group needed for biological 
activity in CoA and ACP (1, 23). 
 However, as D-pantothenic acid becomes relatively unstable, the 
more stable calcium pantothenate becomes in the form of vitamin B5. This is 
usually found in dietary supplements and used basically for study purposes 
(23). 
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Biochemistry 
 Most plants and microorganisms accomplish biosynthesis of 
pantothenic acid by enzymatically combining pantoic acid with β-alanine. 
Mammals and some microbes lack the enzyme for this synthetic step, and so, 
they are unable to synthesize pantothenic acid and need to obtain it from 
outside (23, 30). 
 The biosynthesis of CoA from pantothenic acid is an essential and 
universal pathway in prokaryotes and eukaryotes, and requires cysteine and 
ATP (23, 27, 30). As it is shown in figure 1, CoA is generated from 
pantothenate through a series of five synthetic reactions (23, 27, 30). In the 
synthetic pathway of CoA, pantothenate is first phosphorylated to 4’-
phosphopantothenate by the enzyme pantothenate kinase (CoaA). This step 
is considered the most important control step in the biosynthesis of 
pantothenate-dependent enzymes and it is subjected to feedback regulation 
by CoA itself or its thioester derivatives (27, 30). Furthermore, the next step 
is a condensation reaction with cysteine at the expense of ATP (or CTP in 
bacteria) yielding 4’-phosphopantothenoylcysteine which is decarboxylated 
to form 4’-phosphopantetheine. These two reactions are catalyzed by the 4’-
phosphopantothenoylcysteine synthase (CoaB) and 4’-
phosphopantothenoylcysteine decarboxylase (CoaC) domains of a 
bifunctional enzyme in prokaryotes (CoaBC). In addition, it is also catalyzed 
by two distinct proteins in eukaryotes (PPCS and PPCDC) (27,30). 4’-
Phosphopantetheine is subsequently converted to dephospho-CoA by 
phosphopantetheine adenyltransferase (CoaD), a second rate-limiting 
reaction in the pathway (27, 30). Afterwards, dephospho-CoA is 
phosphorylated by dephospho-CoA kinase (CoaE) at the 3’-OH of the ribose 
to form CoA. The CoaD and CoaE activities are associated with two separate 
enzymes in prokaryotes and plants, but fused in a bifunctional enzyme which 
is termed as CoA synthase (COASY), in mammals (27, 30). 
 In bacteria, the nomenclature for the biosynthetic enzymes is CoaA, 
CoaBC (bifunctional enzyme), CoaD and CoaE for each of the steps 
previously discussed and presented in figure 1. In mammals, the 
corresponding biosynthetic enzymes are PanK, PPCS, PPCDC, and COASY, 
encompassing phosphopantetheine adenyltransferase and dephospho-CoA 
kinase as a unique enzyme. 
 CoA accounts for a large proportion of cellular pantothenic acid, 
although ACP also contains the pantothenic acid molecule (23). However, 
the synthesis of ACP has not yet been elucidated completely (23). 
CoA catabolism occurs as the reverse of the biosynthetic pathway 
except that 4’-phosphopantetheine is converted to pantetheine followed by 
conversion to pantothenic acid by the pantetheinase enzyme (27, 32). In the 
metabolic pathway, CoA is desphosphorylated at the 3’ position of ribose to 
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form dephospho-CoA. Dephospho-CoA is then degraded to 4’-
phosphopantetheine and 5’-AMP. Therefore, dephosphorylation of 4’-
phosphopantetheine forms pantetheine. In the final step of the metabolic 
pathway, pantetheine is hydrolyzed into pantothenic acid and cysteamine by 
the enzyme, pantetheinase (also called vanin). In addition, pantothenic acid 
generated during the CoA degradation is recycled for another biosynthesis of 
CoA or is excreted intact in urine, where it can be measured using a 
Lactobacillus plantarum assay or a radionmunoassay (12). 
Fig. 1. CoA biosynthetic pathway and its key players in bacteria and mammals: ATP, 
adenosine triphosphate; ADP, adenosine diphosphate; CO2, carbon dioxide; PPi, 
pyrophosphate. 
 
Sources and dietary intake 
 Animals and some microbes lack the capacity to synthesize 
pantothenate and are totally dependent on the uptake of exogenous 
pantothenic acid. However, most bacteria such as Escherichia coli, plants, 
and fungi synthesize pantothenic acid, and as such pantothenate is found 
virtually everywhere in biology (27, 30). Pantothenic acid is found both free 
and conjugate in virtually all plant and animal cells (12). However, data on 
the pantothenic acid content of food are very limited. Chicken, beef, 
potatoes, oats, tomato products, liver, kidney, peanuts, almonds, yeast, egg 
yolk, broccoli, cheese, lobster, and whole grains are reported to be the major 
sources of pantothenic acid (12, 23). Also, royal bee jelly and ovaries of tuna 
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and cod have very high levels of pantothenic acid (12). Others such as meats, 
vegetables, milk, and fruits also contain moderate amounts of pantothenic 
acid (30). Processing and refining grains produce a loss of pantothenic acid 
content (12). Ordinary cooking does not cause excessive losses of 
pantothenic acid (12). However, freezing and canning of vegetables, fish, 
meat, and dairy products has been shown to decrease the pantothenic acid 
content of foods (12).   
 The U.S. Institute of Medicine Food and Nutrition Board regularly 
updates dietary guidelines that defines the quantity of each micronutrient that 
is “adequate to meet the known nutrient needs of practically all healthy 
persons” (12). These Recommended Dietary Allowances (RDA) were 
revised between 1998 and 2001 (12). As it was stated in this revision, due to 
lack of suitable data, an Estimated Average Requirement and thus a RDA for 
pantothenic acid in humans of any age cannot be established (12). Therefore, 
the available information on pantothenic acid can only be used to support the 
adequacy of the Adequate Intake (AI), which is the amount to prevent a 
deficiency state of the vitamin (12). The usual pantothenic acid intake is 4 to 
7mg/day, as reported in small groups of adolescents and adults of various 
ages (12). There is no evidence suggesting that this range of intake is 
inadequate. Thus, the approximate midpoint -5mg/day- is set as the AI for 
adults. The AIs in other age groups have been usually calculated by 
extrapolating from adult values (Table 1). 
 Except during pregnancy and lactation, there is no basis for 
determining a separate recommendation based on gender. Thus, the AIs for 
men and women are the same (12). Curiously, a study reported that 
pantothenic acid levels in blood and urine were significantly lower in 
females using oral contraceptives (9 women) compared with four females 
who does not (29). 
 Some studies have shown that certain subsets of the population might 
consume insufficient pantothenate in their diets (23,24). However, it is 
possible that intestinal flora contributes to overall vitamin B5 status in 
humans (23). Intestinal bacteria would produce enough pantothenate to ward 
off signs of a deficiency state in humans (23). However, the contribution of 
bacterial synthesis to body pantothenic acid levels or fecal losses in humans 
has not been quantified (12). 
 Whole blood and urine concentrations of pantothenate are indicators 
of status (12). Although, it is theoretically possible that erythrocyte 
concentrations are a more accurate representation of status than whole-blood 
concentrations because of the contribution of serum pantothenic acid to the 
latter, no clear advantage of using erythrocyte values has been shown (12). 
However, plasma or serum levels are not considered to be accurate for 
measuring pantohenate status (12). 
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• Table 1. Adequate Intake of pantothenic acid in humans according to life 
stage groups, modified from Dietary Reference Intakes: Vitamins (U.S. 
Food and Nutrition Board, released June 12, 2000). 
 
Stage Group    Adequate Intake 
(mg/dl) 
 
Infants 
0 – 6 mo   1.7 
7 – 12 mo   1.8 
Children 
1 – 3 y    2 
4 – 8 y    3 
9 – 13 y   4 
Adolescents 
14 – 18 y   5 
Adults 
19 - > 70 y   5 
Pregnancy 
(any age)    6 
Lactation 
(any age)    7 
 
Deficiency 
 As a consequence of the ubiquitous nature of pantothenic acid, a 
naturally occurring vitamin deficiency in humans either does not occur or 
has not been recognized (27). Presumably even in very poor diets, other 
vitamin deficiencies are limiting factors before pantothenic acid deficiency 
causes definite trouble (23). Actually, our knowledge about pantothenic acid 
deficiency in man comes from some studies on the burning-feet syndrome, a 
disorder which is considered as a natural deficiency state (6, 17). 
Consequently, this is in addition with the investigations inducing 
pantothenate deficiency in healthy volunteers feeding on a devoid diet of 
pantothenic acid, along with the administration of vitamin antagonists (3, 19, 
20, 39).  
 In the Spanish Civil War and among malnourished prisoners held by 
the Japanese in the South of Pacific during the World War II, common 
complaints were numbness and burning pain in the feet (12, 26). Patient’s 
condition was reported to improve by adding rice Polishings and yeast to 
their diet, although not cured completely. Thus, this finding suggested that a 
deficiency of some vitamin B-complex factor was responsible for the disease 
(17, 26). The underlying nutritional disorder was attributed to the deficiency 
of pantothenic acid, riboflavin, nicotinic acid, thiamine, or some 
combinations (26). Pantothenic acid deficiency is now often considered to be 
responsible for these symptoms (12, 26) on the basis of the report by 
Gopalan in 1946 (17). Here, the symptoms were remedied with calcium 
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pantothenate supplementation, but not when other B-complex vitamins were 
administered. However, a later controlled trial carried out in 56 patients from 
a rural area of Sri Lanka did not support these findings. 
 In the mid-to late 1950s, internists William Bean and Robert Hodges 
and their colleagues at the University of Iowa produced experimental 
pantothenic acid deficiency in man by the administration of a vitamin 
antagonist in combination with a deficient pantothenic acid diet (3, 19, 20, 
39). These studies were undertaken in a few healthy volunteers. After taking 
the drug omegamethylpantothenic acid (a pantothenate kinase inhibitor) 
along with a partly synthetic diet deficient in pantothenate, serious clinical 
symptoms appeared within a few weeks. The triad of fatigue (including 
apathy and malaise), headache, and weakness was the most consistent 
finding. Other symptoms included emotional lability, impaired motor 
coordination, paresthesias, burning sensations of the hands and feet, muscle 
cramps, and gastrointestinal disturbance such as nausea, vomiting and 
abdominal cramps. Some subjects had tachycardia, orthostatic hypotension, 
and fluctuations in arterial blood pressure. In some individuals, upper 
respiratory infections were common, while in others, they were not. One 
subject who had many infections had a decrease in gamma globulins, but in 
other subjects, they were normal. Furthermore, other lab abnormalities 
included a reduction in urinary 17-ketosteroids, a loss of the eosinopenic 
response to ACTH, abnormal glucose tolerance, and increased sensitivity to 
insulin (3, 19, 20). Secretion of gastric hydrochloric and pepsin was also 
reduced in these subjects (39).  
 However, we have to emphasize the small number of individuals 
included and the considerable variation in clinical manifestations among 
them particularly in relation to these studies. Moreover, the clinical 
symptoms were unspecific and some artefacts were introduced in the 
experiment due to the nature of the experimental plan. For example, subjects 
were isolated in a ward during the experiment and fed by a gastric tube. 
These conditions may explain some of the emotional alterations that the 
individuals suffered. In addition, one cannot rule out that some of these 
symptoms were not adverse side effects of the administered drug. Finally, 
prompt and complete recovery did not always follow pantothenic acid 
administration. Improvement of the paresthesias and muscle weakness 
usually followed the administration of the vitamin, but fatigue and some 
degree of irritability persisted.  
 Calcium hopantenate has a structural formula similar to that of 
pantothenic acid and is obtained by substituting the β-alanine moiety of 
pantothenic acid for gamma aminobutyric acid (GABA). So, it has a 
GABAergic effect on the central nervous system. Since 1978, this drug has 
been available only in Japan for the treatment of diminished reactivity in 
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organic brain diseases of children and adults. This compound is also a 
pantothenic acid antagonist, with a potency of three times higher than that of 
omega-methyl pantothenic acid (33).  
 Between 1983 and 1985, eleven Japanese children, aged between 9 
months and 10 years, suffered from Reye-like syndrome during calcium 
hopantenate therapy, and seven of them died (33). The duration of 
administration of hopantenate was varied, ranging from 15 days to 15 
months (median: 160 days) and the dosage from 0.5 to 3g per day. Noda et 
al. (33) have reported three additional senile patients who developed fatal 
Reye-like syndrome coincident with treatment of hopantenate for 120 to 124 
days, at a dose of 33 to 58mg/kg/d. Serum levels of pantothenic acid was 
measured in one patient and low levels was found. On the basis of these data, 
the authors speculated with the possibility that the pathogenesis of the Reye-
like syndrome could be due to pantothenic acid deficiency produced by 
calcium hopantenate.  
 Finally, Leonardi et al., in their excellent and exhaustive review 
article on coenzyme A, pointed out that extremely low CoA resulting from 
pantothenate deficiency, either in animals models and humans, is associated 
with hypoglucemia, increased sensitivity to insulin, elevated serum 
triglycerides, and hepatic steatosis (consistent with an inability to degrade 
fatty acids) (27). 
 
Medical aspects 
 Several clinical trials have been undertaken in humans using 
pantothenic acid supplementation and its derivatives in various medical 
fields, such as hyperlipedemia, obesity, acne vulgaris, alopecia, hepatits A, 
lupus erythematosus, osteoarthritis, rheumatoid arthritis, and wound healing 
(1, 21, 23). Unfortunately, a firm conclusions regarding therapeutic 
effectiveness cannot be drawn from many of these studies, given the 
nonrandomized design, statistical biases, confounding variables, and small 
sample size of participating patients.  
 Moreover, specific cysteamine treatment has dramatically changed 
the course of cystinosis (21). Furthermore, recent research on CoA metabolic 
enzymes has led to the discovery of uniquely non-metabolic roles for both 
enzymes and their metabolites, opening a broad field of investigation (32). 
 
Hyperlipidemia  
 The effects of pantethine on the treatment of hyperlipoproteinemia 
have been investigated in numerous studies. Pantethine is a dimer of 
pantothenic acid linked by a disulfide cystamine (see biochemistry). McRae 
has reviewed 28 clinical trials from the literature on this topic, which 
provided a pooled population of 646 hyperlipidemic patients (31). All but 6 
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of these investigations were conducted in Italy (31). Only 4 of the 28 
published studies used a randomized double-blind study design, and only one 
of these was controlled with placebo (31). Oral supplementation of 
pantethine resulted in a tendency toward normalization of lipid values during 
a study period of 4 months (1, 23, 31). Only one study out of these 28 
clinical trials showed results in 9 and 12 months (31). Administration of 
pantethine resulted in a progressive decrease in total cholesterol, 
triglycerides, and low-density lipoprotein cholesterol, along with an increase 
in high-density lipoprotein cholesterol (31), as shown in table 2. However, 
the doses used of pantethine ranged from 300 and 600mg twice daily. The 
most common dosage administration was 300mg 3 times a day (31). The 
mechanism of the action of pantethine in normalizing parameters associated 
with dyslipidemia is unknown, although one can assume it to be secondary to 
the increased levels of intracellular pantothenate coenzymes (1). However, 
two recent papers have not confirmed these data in North American people 
(13, 35). Thus, future randomized, double-blind, and placebo-controlled 
trials with longer intervention are needed to clarify the possible therapeutic 
effect of pantethine on lipids. This is because some methodological 
shortcomings and narrow regional population are involved in these 
investigations (31).  
 A reduction in very low-density lipoprotein cholesterol and 
apolipoprotein A has also been reported in patients treated with pantethine 
(1, 21). No studies have investigated whether pantothenic acid has lipid-
lowering effects. 
Table 2.  Percentage mean change from baseline for serum lipids at months 1 through 4 (31). 
↑: Increase. ↓: Decrease 
 
     1st month 2nd month 3rd month 4th month 
 
Total serum cholesterol    
 chlolesterol   ↓ 8.7% ↓11.6% ↓12.6% ↓15.1% 
Low-density lipoprotein    ↓10.4% ↓15.2% ↓17.7% ↓20.1% 
 chlolesterol 
High-density lipoprotein   ↑ 6.1% ↑ 7.8% ↑10.7% ↑ 8.4% 
 chlolesterol 
Triglycerides    ↓14.2% ↓15.8% ↓23.7% ↓32.9% 
 
 
Platelets 
 Extrinsic factors, such as the plasma lipids, play a major role in the 
regulation of the platelet lipid pattern (21). The platelet membrane lipids 
modulate certain important platelet functions, such as platelet aggregation 
and thromboxane A2 synthesis. Therefore, a number of investigations have 
been performed on the effects of pantethine treatment on the platelet 
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function. It has been shown that oral treatment with pantethine led to 
significant decrease in the total cholesterol and the total phospholipids not 
only in the plasma, but also in the platelets, without any change in their ratio 
(21). The effects of pantethine on the membrane platelet composition may 
influence the fluidity of the cell membranes (1, 21). Thus, it has been 
suggested that pantethine supplementation might prevent atherogenesis in 
man through its effect on serum lipid profile and platelet aggregability (21). 
 The most common serious complication of Plasmodium falciparum 
infection in man is cerebral malaria, with a case fatality rate of 20 to 50% 
(14). The pathogenesis of cerebral malaria is currently viewed in relation to 
the process of sequestration of parasitized erythrocytes in the cerebral 
microvasculature (14). Among other pathogenic mechanisms, the process is 
accompanied by platelet and endothelial cell activation (14). An 
investigation has shown that infected mice with P. berghei did not develop 
the cerebral syndrome when pantethine was administered (34). The 
protection was associated with down-regulation of platelet responsiveness 
and impairment of endothelial cell activation (34). In this experiment, 
parasite development was unaffected by panthetine, as infected mice who 
escaped from cerebral malaria died of high parasitemia (34). Unfortunately, 
neither this nor any other experimental malaria model provides a reliable 
representation of human cerebral malaria (14).   
 
Cystinosis 
 For now, therapy of cystinosis relies on the aminothiol cysteamine (4, 
5, 16, 44). Cystinosis is a rare autosomal recessive disorder with an 
estimated incidence of 1 case per 100,000 to 200,000 live births (16).  It is 
caused by mutations in the gene CTNS, and is mapped to chromosome 
17p13, which encodes cystinosin, a lysosomal cystine transporter (5, 16, 44). 
However, defects in this transporter lead to the accumulation of 
intralysosomal cystine crystals and widespread cellular destruction. The 
predominant pathological finding in cystinosis is the presence of cystine 
crystals in almost all cells and tissues, including the conjunctivae, corneas, 
liver, spleen, lymph nodes, kidneys, thyroid, intestines, rectal mucosa, 
muscle, brain, macrophages, and bone marrow (5, 16).  The disease is 
manifested as a multisystem disorder that affects the kidney (Fanconi 
syndrome, renal failure), the eyes, muscles, central nervous system, lungs, 
and various endocrine organs. Nevertheless, kidney involvement remains the 
earliest and foremost clinical characteristic of the disorder. 
 The mainstay of cystinosis therapy is oral cysteamine bitartrate (trade 
name Cystagon®, Mylan Pharma, USA), an aminothiol that can lower 
intracellular cystine content by 95% (16, 44). Consequently, cysteamine is 
administered in four divided doses; but newly long-acting, enteric-coated 
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formulations are available (called RP103) by Raptor Pharmaceutical Corp. 
(USA), which can be administered twice a day (4, 5). The mechanism of 
intralysosomal cystine depletion involves entry of cysteamine into the 
lysosomal compartment through a specific transporter, and a disulfide 
reaction with cystine, resulting in the equimolar generation of a cysteine-
cysteamine molecule and a molecule of cysteine. Both compounds can exit 
lysosomes via “system c” transporters, bypassing the defective cystinosin 
pathway (5, 16, 44). In well-treated children, cysteamine has proven efficacy 
in delaying renal glomerular deterioration, enhancing growth, and preventing 
hypothyroidism (4, 5, 16, 44). Corneal cystine crystals do not dissolve with 
oral cysteamine therapy, but do respond to the administration of cysteamine 
eyedrops (5). Therefore, the U.S. Food and Drug Administration (FDA) has 
approved a formulation for this purpose.   
 Approximately 14 percent of patients are unable to tolerate 
cysteamine therapy because of nausea and vomiting (5). Intracellular 
cysteamine is produced by the action of the enzyme pantetheinase on 
pantetheine. Pantethine, the disulfide dimer of pantetheine, was proven in the 
treatment of four cystinotic children (45). Thus, pantethine is non-toxic and 
more palatable than cysteamine. The authors concluded that pantethine had 
less efficacy than cysteamine to deplete leukocytes from cystine; and 
therefore, it should only be considered in cases of cysteamine intolerance 
(45). 
 
Miscellaneous Medical Uses 
 An open-label study included one hundred patients with acne to be 
treated with high doses of pantothenic acid (10g/day in four divided doses) 
for eight weeks or longer. The authors reported that the disease was usually 
controlled by eight weeks in cases of moderate severity (23). A recent paper 
has indicated that the administration of a pantothenic acid-based dietary 
supplement in healthy adults with facial acne lesions reduced total facial 
lesion after 12 weeks of supplementation (2.2g/day of pantothenic acid) (46). 
 A study used pantothenic acid at a dose of 100mg/day for 4-5 months 
to treat diffuse alopecia in women. No beneficial effects could be 
demonstrated (23). 
 One hundred obese patients of Chinese descent were treated with 
pantothenic acid (10 g/day in four divided does) along with a calorie 
restricted diet. The authors noted an average weight loss of 1.2 Kg per week 
and no side effects were observed (23). 
 A randomized, double-blind, and placebo-controlled study compared 
the effect of pantothenic acid and L-cysteine in the treatment of osteoarthritis 
of the knees. Thus, no difference was observed either subjectively or 
objectively between the two groups (23). 
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 By the early 1960s, the effects of intramuscular daily injection of 
calcium-D-pantothenate into patients with rheumatoid arthritis were tested 
(2). The authors reported temporary alleviation of symptoms and no uniform 
success.  
 The efficacy of panthenol for pediatric post-tonsillectomy pain and 
wound healing has been evaluated (45). Panthenol (synonyms: D-panthenol 
or dexpanthenol) is a stable alcoholic analogue of pantothenic acid. 
Postoperative administration of panthenol significantly accelerated the 
wound healing process and reduced tonsillectomy-related complaints, 
independently of the surgical technique used. The mechanism(s) of the 
action of panthenol for these effects remains elusive (7). 
 The effect of oral supplementation of 1.5g/day each of D-pantothenic 
acid and L-cysteine on exercise performance was examined in eight healthy 
male volunteers aged 22.9 ± 1.4 years (41). The conclusion of this study was 
that “acute feeding with pantothenate and cysteine does not alter muscle 
CoA content and consequently does not affect muscle fuel metabolism or 
performance during exercise in humans”.  
 Recently, cysteamine has been used in the treatment of non-alcoholic 
fatty liver disease in children with promising results (5). Moreover, some 
experimental and clinical data support the usefulness of cysteamine in the 
treatment of patients with Huntington Disease. Thus, a randomized, 
controlled, and double-blind multicenter phase II-III trial using RP103 
cysteamine formulation is currently underway (5). In addition, some animal 
studies have suggested that cysteamine might also be beneficial in the 
treatment of Parkinson’s disease, as well as in certain neuropsychiatric 
disturbances, such as schizophrenia and major depressive disorders (5). 
 Finally, during the last few decades, the inhibition of the metabolism 
of CoA is being extensively investigated in relationship to its potential 
antimicrobial effect. A breakthrough discovery was the molecular cloning of 
genes encoding CoA biosynthetic pathway enzymes (27,30), of the 
pantothenate kinases in particular. These enzymes have been divided into 
four groups based on their amino acid sequences, i.e., prokaryotic type I, II, 
and III CoaAs and eukaryotic PanK (27). Type I and III CoaAs are widely 
distributed among bacteria, while the type II CoaA is limited to 
staphylococci. The requirement for CoA in numerous metabolic bacterial 
processes and the diversity amongst the structure of pantothenate kinase in 
bacteria and mammals have made these enzymes an attractive drug targets 
for the development of novel antimicrobial agents (27,30). Pantothenamides, 
and amides derived from pantothenic acid, are substrates of the key rate-
limiting enzyme pantothenate kinase (CoaA). N-pentylpantothenamide (N5-
Pan) and N-heptylpantothenamide (N7-Pan) are the prototypes of pantothen. 
However, only Gram-positive bacteria are sensitive to pantothenamide at 
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pharmaceutically realistic concentrations (22). In addition, they have also 
been shown to possess activity against fungi and malaria parasites (22). It 
was thought that the mechanism of action of pantothenamides was the 
formation of CoA analogs that lead to the transfer of an inactive 4’-
phoshopantothenamide moiety to ACP, which is the first step in the bacterial 
type II route of fatty acid synthesis (10,22,28). However, the precise 
mechanism by which pantothenamides act to inhibit bacterial viability is not 
yet completely resolved, because pantothenate supplementation do not revert 
this effect (22). However, two recent papers have shown that the 
antibacterial (22) and anti-malaria (37) activities of pantothenamides might 
be increased through the inactivation of the enzyme pantetheinase. 
 Another compound, the antibiotic CJ-15,801 was discovered by 
Sugie et al. at Pfizer Laboratories in 2001, from the fermenting cultures of a 
Sematosporium sp. fungus (40). Structural analysis showed the compound 
resembles pantothenic acid, with the notable exception of a trans-substituted 
double bound in the β-alanine moiety. CJ-15,801, like pantothenamides, 
selectively inhibits the growth of Staphylococcus aureus and the 
intraerythrocytic growth stage of the malaria parasite Plasmodium 
falciparum (40). The basis for CJ-15,801’s unique antimicrobial specificity 
may also be based on the type-specificity of their pantothenate kinases, both 
of which have been characterized as type II enzymes (40).  Van der 
Westhuyzen et al. have demonstrated that CJ-15,801 acts as an 
antimetabolite against staphylococci using the first enzyme of the CoA 
biosynthesis to enter the pathway, after which it inhibits the second CoA 
biosynthesis enzyme, poshopantothenoylcysteine synthase, by forming a 
tight-binding inhibitor in situ (40). This mode of action is reminiscent of the 
sulphonamide antibiotics, which block folic acid biosynthesis using a similar 
strategy. 
 Pantothenol is an alcoholic analogue of the pantothenic acid, which is 
widely used in health-care and cosmetic industries (see below). Pantothenol 
has been reported to reduce the activities of type I and II CoaAs, with a more 
potent effect being observed on the type II CoaA than on the type I CoaA. 
By contrast, the type III CoaA is not inhibited by pantothenol (9). Thus, 
pantothenol has been shown to markedly inhibit the phosphorylation activity 
of pantothenate kinases in vitro of Escherichia coli and staphylococci (9). 
The growth of Mycobacterium tuberculosis is also inhibited by pantothenol 
(25). At the same time, Saliba et al. showed that pantothenol inhibited the in 
vitro growth of Plasmodium falciparum (36). The authors speculated that the 
mechanism might involve the competition with pantothenate, inhibiting the 
activity of the parasite’s pantothenate kinase.    
 Therefore, the antimicrobial properties of the inhibitors of the 
metabolism of the CoA are an exciting and promising field of research.   
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Tolerable upper intake level and adverse side effects  
 Tolerable Upper Intake Level (UL) is the maximum level of daily 
nutrient intake that is likely to pose no adverse health risks (12). The UL 
represents total intake from food, water, and supplements. However, there is 
no sufficient scientific evidence on which to base a UL for pantothenic acid 
(12). Evidence available from clinical studies using high doses of 
pantothenic acid indicates that intake considerably in excess of 5mg do not 
represent a health risk for the general population (23).  
 On the other hand, the existing clinical studies on pantothenic acid 
were not designed to monitor and assess side effects. Thus, information of 
the adverse effects on human is limited. The most commonly reported side 
effect is mild transient gastrointestinal disturbance such as nausea, heartburn, 
and diarrhea (1, 23, 31). Adverse effects typically do not occur until doses 
exceed 1 gram daily (23). In doses of 10g/day, diarrhea is reported to occur. 
Furthermore, there has been one case report of eosinophilic pleuropericardial 
effusion in a patient taking 300mg/day of pantothenic acid in combination 
with 10g/day of biotin for two months. Hence, the condition was resolved 
after the vitamins were stopped (11). 
 Panthenol, the alcoholic analogue of pantothenic acid, is widely used 
in a variety of cosmetics, topical medical, over-the-counter, and in 
photoprotective products (22, 23, 28, 37). Because of its moisturizing and 
conditioning properties, it is mainly used in hair preparations. Nevertheless, 
it is also added to other products. Allergic contact dermatitis caused by 
panthenol is considered to be rare, but has been occasionally reported 
following the use of medications, moisturizers, and sunscreens (8, 15, 18). 
 Pantothenic acid has an FDA Use-in-Pregnancy category A rating for 
doses at or below Adequate Intake. What this means is that “well-controlled 
studies have failed to demonstrate a risk to the fetus in the first trimester of 
pregnancy (and there is no evidence of risk in the later trimester)” for doses 
at or below this level (23). Higher doses of pantothenic acid have a 
Pregnancy category C rating (23). Cysteamine is also classified as a 
Pregnancy category C drug (5). That is to say that “animal reproduction 
studies have shown an adverse effect on the fetus and there are no adequate 
and well-controlled studies in humans, but potential benefits may warrant the 
use of the drug in pregnant women despite the potential risks”.  
 
Conclusion 
 Pantothenic acid is a naturally occurring physiological compound, 
which offers potential effective therapeutic actions on diverse clinical 
conditions. The proper role of pantothenic acid in the therapeutic 
armamentarium is still challenging to proper answer. In light of the potential 
therapeutic benefit of pantothenic acid and its derivatives and the lack of 
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adverse reactions, there is a need to address the issue of treatment with this 
compound. Since cysteamine has been useful in the treatment of cystinosis, it 
is possible that other clinical conditions may benefit the treatment with this 
compound. In our opinion, pantothenic acid (and its derivatives) deserves 
much more attention than it has received now. 
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